1. Home
  2. GMAB vs NWSA Comparison

GMAB vs NWSA Comparison

Compare GMAB & NWSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMAB
  • NWSA
  • Stock Information
  • Founded
  • GMAB 1999
  • NWSA 2012
  • Country
  • GMAB Denmark
  • NWSA United States
  • Employees
  • GMAB N/A
  • NWSA N/A
  • Industry
  • GMAB Biotechnology: Pharmaceutical Preparations
  • NWSA Newspapers/Magazines
  • Sector
  • GMAB Health Care
  • NWSA Consumer Discretionary
  • Exchange
  • GMAB Nasdaq
  • NWSA Nasdaq
  • Market Cap
  • GMAB 17.4B
  • NWSA 16.0B
  • IPO Year
  • GMAB N/A
  • NWSA N/A
  • Fundamental
  • Price
  • GMAB $32.12
  • NWSA $26.79
  • Analyst Decision
  • GMAB Strong Buy
  • NWSA Strong Buy
  • Analyst Count
  • GMAB 7
  • NWSA 7
  • Target Price
  • GMAB $41.17
  • NWSA $38.28
  • AVG Volume (30 Days)
  • GMAB 2.2M
  • NWSA 4.7M
  • Earning Date
  • GMAB 11-05-2025
  • NWSA 11-06-2025
  • Dividend Yield
  • GMAB N/A
  • NWSA 0.74%
  • EPS Growth
  • GMAB 77.72
  • NWSA 345.01
  • EPS
  • GMAB 21.62
  • NWSA 2.07
  • Revenue
  • GMAB $3,646,881,232.00
  • NWSA $8,452,000,000.00
  • Revenue This Year
  • GMAB $24.25
  • NWSA $4.71
  • Revenue Next Year
  • GMAB $16.29
  • NWSA $3.51
  • P/E Ratio
  • GMAB $1.51
  • NWSA $13.06
  • Revenue Growth
  • GMAB 32.97
  • NWSA 2.42
  • 52 Week Low
  • GMAB $17.24
  • NWSA $23.38
  • 52 Week High
  • GMAB $33.63
  • NWSA $31.61
  • Technical
  • Relative Strength Index (RSI)
  • GMAB 72.36
  • NWSA 28.40
  • Support Level
  • GMAB $28.36
  • NWSA $26.82
  • Resistance Level
  • GMAB $33.63
  • NWSA $31.61
  • Average True Range (ATR)
  • GMAB 0.62
  • NWSA 0.63
  • MACD
  • GMAB 0.11
  • NWSA -0.40
  • Stochastic Oscillator
  • GMAB 72.68
  • NWSA 1.15

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About NWSA News Corporation

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

Share on Social Networks: